An et al. [26] reported that radiogenomics features are associated with Mammalian target of rapamycin (mTOR) pathway gene activity in hepatocellular carcinoma (HCC), where the mTOR signalling pathway governs cellular activities and offers opportunities for targeted anti-tumour treatment. This evidence concerns the gene MTOR and hepatocellular carcinoma.